Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen del Rocío (222)

2024

  1. Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

    AIDS Patient Care and STDs, Vol. 38, Núm. 7, pp. 305-314

  2. Blood gene expression biomarkers of response to anti-TNF drugs in pediatric inflammatory bowel diseases before initiation of treatment

    Biomedicine and Pharmacotherapy, Vol. 173

  3. Correction to: Spanish registry of hemoglobinopathies and rare anemias (REHem-AR): demographics, complications, and management of patients with β-thalassemia (Annals of Hematology, (2024), 103, 5, (1525-1539), 10.1007/s00277-024-05694-z)

    Annals of Hematology

  4. Haemoglobinopathies and other rare anemias in Spain: ten years of a nationwide registry (REHem-AR)

    Annals of Hematology, Vol. 103, Núm. 8, pp. 2743-2755

  5. Human gut microbiota analysis of cystic fibrosis infants using metaproteomics

    Microbiology Resource Announcements, Vol. 13, Núm. 6

  6. JAK inhibitor treatment for inborn errors of JAK/STAT signaling: An ESID/EBMT-IEWP retrospective study

    Journal of Allergy and Clinical Immunology, Vol. 153, Núm. 1, pp. 275-286.e18

  7. Palliative care for children with central nervous system tumors: results of a Spanish multicenter study

    Clinical and Translational Oncology, Vol. 26, Núm. 3, pp. 786-795

  8. Re-irradiation for progressive Diffuse Intrinsic Pontine Glioma (DIPG): The Spanish experience

    EJC Paediatric Oncology, Vol. 4

  9. Spanish registry of hemoglobinopathies and rare anemias (REHem-AR): demographics, complications, and management of patients with β-thalassemia

    Annals of Hematology, Vol. 103, Núm. 5, pp. 1525-1539

  10. Tuberculosis Disease in Immunocompromised Children and Adolescents: A Pediatric Tuberculosis Network European Trials Group Multicenter Case-control Study

    Clinical Infectious Diseases, Vol. 79, Núm. 1, pp. 215-222

2023

  1. Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity

    Journal of Allergy and Clinical Immunology, Vol. 152, Núm. 4, pp. 984-996.e10

  2. Adequacy of the 10 mg/kg Daily Dose of Antituberculosis Drug Isoniazid in Infants under 6 Months of Age

    Antibiotics, Vol. 12, Núm. 2

  3. Antimicrobial Defined Daily Dose in Neonatal Population: Validation in the Clinical Practice

    Antibiotics, Vol. 12, Núm. 3

  4. Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort

    International Journal of Molecular Sciences, Vol. 24, Núm. 2

  5. Comments on: Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children

    Pharmacological Research

  6. Experience With Elexacaftor/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and Advanced Disease

    Archivos de Bronconeumologia, Vol. 59, Núm. 9, pp. 556-565

  7. Failure of early non-invasive ventilation in preterm infants with respiratory distress syndrome in current care practice in Spanish level-III neonatal intensive care units – a prospective observational study

    Frontiers in Pediatrics, Vol. 11

  8. Long-term evolution in liver disease markers and immune and lipid profiles in vertically HIV/HCV-coinfected youths with sustained viral response after direct-acting antivirals therapy

    Biomedicine and Pharmacotherapy, Vol. 162

  9. Monogenic early-onset lymphoproliferation and autoimmunity: Natural history of STAT3 gain-of-function syndrome

    Journal of Allergy and Clinical Immunology, Vol. 151, Núm. 4, pp. 1081-1095

  10. Polymorphisms indicating risk of inflammatory bowel disease or antigenicity to anti-TNF drugs as biomarkers of response in children

    Pharmacological Research, Vol. 194